CSF2 and posterior cortical atrophy: Replication-competent HAd5/3 chimeric viruses expressing GM-CSF (Oncos-102, HAd5/3-D24-GM-CSF) were tested in a phase I clinical trial to target solid tumors.96,97 Since then, Oncos-102 has been tested in a phase I clinical trial, and in combination with durvalumab and autologous dendritic cell immunotherapy (DCVAC/PCa) in phase I/II trials for treating solid tumors (NCT01598129, NCT02963831, and NCT03514836).